Skip to main content
SpringerLink
Log in

Angiosuppressive and Antiproliferative Actions of Suramin: A Growth Factor Antagonist

  • Chapter
Growth Factors, Peptides and Receptors

Abstract

Suramin is a novel anticancer agent1 that appears to be effective against advanced adrenocortical carcinoma2,3, prostatic cancer4,5, ovarian cancer6, renal cell carcinome and certain refractory lymphomas8. The antiproliferative action is possibly related to the ability of suramin to block the binding of autocrine growth factors to their receptors9-18, to inhibit a variety of cytoplasmic and intranuclear enzymes critical for cell maintenance and proliferation19,20, and to disrupt cellular respiration and energy balance21. Cell migration and adhesion of B16 melanoma cells to the extracellular matrix is inhibited following suramin exposure 22,23 suggesting a mechanism for suramin to inhibit tumor invasion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. RV. La Rocca, C.A. Stein, and C.E. Myers, Suramin: Prototype of a new generation of antitumor compounds. Cancer Cells. 2: 106 (1990).

    PubMed  Google Scholar 

  2. C.A. Stein, R.V. La Rocca, R. Thomas, N. McAtee, and C.E. Myers, Suramin: An anticancer drug with unique mechanism of action, J Clin Oncol. 7: 499 (1989).

    PubMed  CAS  Google Scholar 

  3. R.V. La Rocca, C.A. Stein, R. Danesi, C. Jamis-Dow, G.H. Weiss, and C.E. Myers, Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro and clinical antitumor effect. J Clin Endocrinol Metab. 71: 497 (1990).

    Article  PubMed  Google Scholar 

  4. RV. La Rocca, M.R. Cooper, and M. Uhrich, The use of suramin in the treatment of prostate cancer refractory to conventional hormonal manipulation. Urol Clin North Am. 18: 123 (1991).

    Google Scholar 

  5. C.M. Myers, M. Cooper, C. Stein, La Rocca, R, M.M. Walther, G. Weiss, P. Choyke, N. Dawson, S. Steinberg, M.M. Uhrich, J. Cassidy, D.R. Kohler, J. Trepel, and DR. Linehan, Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 10: 881 (1992).

    CAS  Google Scholar 

  6. E. Reed, M.R. Cooper, R.V. La Rocca, F. Bostick-Bruton, and C.E. Myers, Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer. 28A: 864 (1992).

    Article  PubMed  CAS  Google Scholar 

  7. RV. La Rocca, C.A. Stein, R. Danesi, M.R. Cooper, M. Uhrich, and C.E. Myers, A pilot study of suramin in the treatment of metastatic renal carcinoma. Cancer. 67: 1509–1513 (1991).

    Article  PubMed  Google Scholar 

  8. R.V. La Rocca, C.E. Myers, C.A. Stein, M.R. Cooper, and M. Uhrich, Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy. Proc Am Soc Clin Oncol. 9: 1041 (1990)

    Google Scholar 

  9. M. Hosang, Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 29: 265 (1985).

    Article  PubMed  CAS  Google Scholar 

  10. C. Betsholtz, A. Johnson, C.H. Heldin, and B. Westermark, Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA. 83: 6440 (1986).

    Article  PubMed  CAS  Google Scholar 

  11. L.T. Williams, P. Tremble, M.F. Lavin, and M.E. Sunday, Platelet-derived growth factor receptors from a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem. 259: 5287 (1984).

    PubMed  CAS  Google Scholar 

  12. R.J. Coffey, E.B. Leof, G.D. Shipley, and H.L. Moses, Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-28 cells. J Cell Physiol. 132: 143 (1987).

    Article  PubMed  CAS  Google Scholar 

  13. S. Olivier, P. Formento, J.L. Fischel, M.C. Etienne, and G. Milano, Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J. Cancer. 26: 867 (1990).

    CAS  Google Scholar 

  14. D.A. Lappi, PA. Maher, D. Martineau, and A. Baird, The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J Cell Physiol. 147: 17 (1991).

    Article  PubMed  CAS  Google Scholar 

  15. A. Wellstein, R. Lupu, C. Zugmaier, S.L. Flamm, A.L. Cheville, P. Delli-Bovi, C. Basilico, M.E. Lippman, and F.G. Kern, Autocrine growth stimulation by secreted kaposi fibroblast growth factor but not by endogeneous basic fibroblast growth factor. Cell Growth Diff. 1: 63 (1990).

    PubMed  CAS  Google Scholar 

  16. M. Pollak and M. Richard, Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells. J Nat Cancer Inst. 82: 1349 (1990).

    Article  PubMed  CAS  Google Scholar 

  17. C.P. Minniti, M. Maggi, and L.J. Heiman, Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 52: 1830 (1992)

    PubMed  CAS  Google Scholar 

  18. G.B. Mills, N. Zhang, C. May, M. Hill, and A. Chung, Suramin prevents binding of interleukin-2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res. 50: 3036 (1990).

    PubMed  CAS  Google Scholar 

  19. Z. Spiegelman, A. Dowers, S. Kennedy, D. DiSorbo, M. O’Brien, R. Barr, and R. McCaffrey, Antiproliferative effects of suramin on lymphoid cells. Cancer Res. 47: 4694 (1987).

    Google Scholar 

  20. K. Ono, H. Nakane, and M. Fukushima, Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin. Eur J Biochem. 172: 349 (1988).

    Article  PubMed  CAS  Google Scholar 

  21. R. Rago, J. Mitchen, A.L. Cheng, T. Oberley, and G. Wilding, Disruption of cellular energy by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. Cancer Res. 51: 6629 (1991).

    PubMed  CAS  Google Scholar 

  22. M. Nakajima, A. De Chavigny, C.E. Johnson, J. Hamada, and C.A. Stein, Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem. 266: 9661 (1991).

    PubMed  CAS  Google Scholar 

  23. V.S. Zabrenetzky, E.C. Kohn, and D.D. Roberts, Suramin inhibits laminin-and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res. 50: 5937 (1990).

    PubMed  CAS  Google Scholar 

  24. J. Folkman, What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82: 4 (1990).

    Article  PubMed  CAS  Google Scholar 

  25. J. Folkman, Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg. 175: 409 (1972).

    Article  PubMed  CAS  Google Scholar 

  26. J. Folkman and M. Klagsbrun, Angiogenic factors. Science. 235: 442 (1987).

    Article  PubMed  CAS  Google Scholar 

  27. J.L. Gross, R.S. Morrison, K. Eidsvoog, W.F. Herblin, P.L. Komblith, and D.L. Dexter, Basic fibroblast growth factor: a potentiate autocrine regulation of human glioma cell growth. J Neurosci Res. 27: 689 (1990)

    Article  PubMed  CAS  Google Scholar 

  28. T-P.D. Fan and S. Brem, Angiosuppression, in: “The Search For New Anticancer Drugs, Cancer Biology Series. Vol 3., pp185–229.” M.J. Waring, and B. Ponder, ed., Kluwer Publishers, Lancaster, UK (1992).

    Google Scholar 

  29. N. Vaisman, D. Gospodarowicz, and G. Neufeld, Characterization of the receptors for vascular endothelial cell growth factor. J Biol Chem. 256: 19461 (1990).

    Google Scholar 

  30. M. Home, C.A. Stein, R.V. La Rocca, and C.E. Myers, Circulating glycosaminoglycan anticoagulant associated with suramin treatment. Blood. 71: 273 (1988).

    Google Scholar 

  31. C.A. Janis-Dow, G.H. Weiss, and M.J. Merino, Suramin selectively localizes to vascular endothelial cells: a possible basis for the antiangiogenesis activity of suramin (abstr). Proc Am Assoc Cancer Res. 31: 60 (1990).

    Google Scholar 

  32. R. Sato and D.B. Rifkin, Autocrine activities of basic fibroblast factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol. 107: 1199 (1988).

    Article  PubMed  CAS  Google Scholar 

  33. S. Takano, S. Gately, A.M.C. Tsanaclis, H. Engelhard, J.L. Gross, WE Herblin, K. Eidsvoog, and S. Brem, Inhibition of angiogenesis and the proliferation of endothelial and glioma cells by suramin in vitro and in situ in the brain. (Manuscript in preparation).

    Google Scholar 

  34. H.I. Scher, D.I. Jodrell, J.M. Iversen, T. Curley, W. Tong, M.J. Egorin, and A. Forrest, Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52: 64 (1992).

    PubMed  CAS  Google Scholar 

  35. M.R. Cooper, R. Lieberman, R.V. La Rocca, P.R. Germ, M.S. Weinberger, DJ. Headlee, D.R. Kohler, B.R. Goldspiel, C.C. Peck, and C.E. Myers, Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther. 52: 11 (1992).

    Article  PubMed  CAS  Google Scholar 

  36. K.J. Pienta, W.B. Isaacs, D. Vindivich, and D.S. Coffey, The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol. 145, 199 (1991).

    PubMed  CAS  Google Scholar 

  37. XJ. Guo, J. Fantini, R. Roubin, J. Marvaldi, and G. Rougon, Evaluation of the effect of suramin on neural cell growth and N-CAM expression. Cancer Res. 30: 5164 (1990).

    Google Scholar 

  38. E.M. Berns, A.L. Schuurmans, D.J. Lamb, J.A. Foekens, and E. Mulder, Antiproliferative effects of suramin on androgen responsive tumor cells. Eur J Cancer. 26: 470 (1990).

    Article  PubMed  CAS  Google Scholar 

  39. I. Tannock, Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 30: 2470 (1970).

    PubMed  CAS  Google Scholar 

  40. K. Forsbeck, K. Bjelkenkrantz, and K. Nilsson, Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: Effects of suramin and a lipophilic iron chelator (PIH). Scand J Haematol. 37: 429 (1986).

    Article  PubMed  CAS  Google Scholar 

  41. H, Jindal, C.W. Anderson, R.G. Davis, and J.K. Vishwanatha, Suramin affects DNA synthesis in Hela cells by inhibition of DNA polymerases. Cancer Res. 50: 7754 (1990).

    PubMed  CAS  Google Scholar 

  42. P. Michel, R.V. Velthoven, M. Petein, S. Gras, C. Etievant, J.L. Pasteels, and R. Kiss, Influence of suramin alone or in combination with DHT and PDGF on the cell proliferation of benign and malignant human prostatic tissues in organ cultures. Anticancer Res. 11: 2075 (1991).

    PubMed  CAS  Google Scholar 

  43. J.H. Kim, E.R. Sherwood, D.M. Sutkowsld, C. Lee, and J.M. Kozlowski, Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J. Urol. 146: 171 (1991).

    PubMed  CAS  Google Scholar 

  44. T.M. Walz, A. Abdiu, S. Wingren, S. Smeds, S.E. Larsson, and A. Wasteson, Suramin inhibits growth of human osteosarcoma xenografts in nude mice. Cancer Res. 51: 3585 (1991).

    PubMed  CAS  Google Scholar 

  45. P.N. Dean, E Dolbeare, H. Gratzner, G.C. Rice, and J.W. Gray, Cell-cycle analysis using a monoclonal antibody to BrdUrd. Cell Tissue Kinet. 17: 427 (1984).

    PubMed  CAS  Google Scholar 

  46. L.E. Odekon, Y. Sato, D.B. Rifkin, Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 150: 258 (1992).

    Article  PubMed  CAS  Google Scholar 

  47. D.H. Ausprunk, D.R. Knighton, and J. Folkman, Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois: role of host and preexisting graft blood vessels. Am J Pathol. 79: 597 (1975).

    PubMed  CAS  Google Scholar 

  48. M. Ciomei, E. Pesenti,F. Sola, W. Pastori, M. Mariani, M. Grandi, and E Spreafico, Antagonistic effect of suramin on bFGF: In vitro and in vivo results. Int J Radial Biol. 60: 78 (1991).

    Article  Google Scholar 

  49. J.W. Wilks, P.S. Scott, L.K. Vrba, and J.M. Cocuzza, Inhibition of angiogenesis with combination treatment of angiostatic steroids and suramin. Int J Radial Biol. 60: 73 (1991).

    Article  CAS  Google Scholar 

  50. F. San-Galli, P. Vrignaud, J. Robert, J.M. Coindre, and F. Cohadon Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats. J Neuroonc. 7: 299 (1989).

    CAS  Google Scholar 

  51. M.T. Giordana, I. Germanol, G. Giaccone, A. Muro, and D. Schiffer, The distribution of laminin in human brain tumors: an immunohistochemical study. Acta Neuropathol (Berl). 67: 51 (1985).

    Article  CAS  Google Scholar 

  52. M. Eriksdotter-Nilsson, H. Bjorklund, and L. Olson, Laminin immunohistochemistry: a simple method to visualize and quantitate vascular structures in the mammalian brain. J Neurosci Meth. 17: 275 (1986).

    Article  CAS  Google Scholar 

  53. S. Baghdiguian, P. Nickel, and J. Fantini, Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity. Cancer Letters. 60: 213 (1991).

    Article  PubMed  CAS  Google Scholar 

  54. J.P. Friehauf, C.E. Myers, and B.K. Sinha, Synergistic activity of suramin with tumor necrosis factor-a and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst. 82: 1206 (1990).

    Article  Google Scholar 

  55. S. Liu, M.W. Ewing, P. Anglard, E. Trahan, R.V. La Rocca, C.E. Myers, and W.M. Linehan, The effect of suramin, tumor necrosis factor and interferon-y on human prostate carcinoma. J Urol. 145: 389 (1991).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurological Surgery, Northwestern Memorial Hospital and School of Medicine, Chicago, Illinois, 60611, USA

    Shingo Takano, Stephen Gately, Herbert Engelhard, Ana Maria C. Tsanaclis & Steven Brem

  2. Du Pont Merck Pharmaceutical Corporation, Wilmington, Delaware, 19880-0400, USA

    Janet L. Gross, William E Herblin, Kristi Eidsvoog & Mary Neville

  3. 233 East Erie St, Suite 500, Chicago, Illinois, 60611-2906, USA

    Steven Brem

Authors
  1. Shingo Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Gately
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Herbert Engelhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Maria C. Tsanaclis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janet L. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William E Herblin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kristi Eidsvoog
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mary Neville
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steven Brem
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The George Washington University Medical Center, Washington, DC, USA

    Terry W. Moody

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Plenum Press, New York

About this chapter

Cite this chapter

Takano, S. et al. (1993). Angiosuppressive and Antiproliferative Actions of Suramin: A Growth Factor Antagonist. In: Moody, T.W. (eds) Growth Factors, Peptides and Receptors. GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2846-3_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2846-3_24

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-44484-5

  • Online ISBN: 978-1-4615-2846-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation